Aclaris Therapeutics Inc Stock Price, News & Analysis

Aclaris Therapeutics (NASDAQ: ACRS) announced new employee equity grants under its 2024 Inducement Plan. The company granted nonstatutory stock options to purchase 251,000 shares and 73,000 restricted stock units to 4 new employees. Additionally, Hugh Davis, Ph.D, the new President and Chief Operating Officer, received options to purchase 375,000 shares and 107,000 restricted stock units.

The options have an exercise price of $3.96 per share, matching the closing price on December 2, 2024. Both options and restricted stock units will vest 25% annually over four years, contingent on continued employment. These grants were made as employment inducements in accordance with NASDAQ Listing Rule 5635(c)(4).

Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management team will engage in a fireside chat on Tuesday, December 3, 2024, at 1:00 PM ET in New York.

Interested parties can access the webcast through the 'Events' page in the 'Investors' section of Aclaris' website. The recording will remain available for a minimum of 30 days on www.aclaristx.com.

Biosion has entered into an exclusive license agreement with Aclaris Therapeutics (NASDAQ: ACRS) for worldwide rights (excluding Greater China) to two immunology assets: BSI-045B and BSI-502. The deal includes an upfront payment of over $40 million, 19.9% of Aclaris common stock, and potential milestone payments exceeding $900M with tiered royalties.

BSI-045B, a clinical-stage anti-TSLP antibody, has shown promising results in a Phase 2a trial for atopic dermatitis with 22 patients. BSI-502 is a pre-clinical stage bispecific antibody targeting both TSLP and IL4R. The agreement grants Aclaris development and commercialization rights worldwide, except for Greater China.

Aclaris Therapeutics (NASDAQ: ACRS) has secured an exclusive global license agreement with Biosion for worldwide rights (excluding Greater China) to two key biologics: BSI-045B, a clinical-stage anti-TSLP monoclonal antibody, and BSI-502, a pre-clinical stage bispecific antibody targeting TSLP and IL4R. BSI-045B has shown promising results in a Phase 2a trial for atopic dermatitis with 22 patients. The company also announced the appointment of two new executives: Hugh Davis as President and COO, and Steven Knapp as EVP, Head of Regulatory & Quality. The agreement strengthens Aclaris' pipeline in immunology with both small and large molecule drugs.

Aclaris Therapeutics (NASDAQ: ACRS) has secured a $80 million private placement through the sale of 35,555,555 shares of common stock at $2.25 per share. The placement was led by Vivo Capital, with participation from both new and existing investors including Forge Life Science Partners, Rock Springs Capital, and RA Capital Management, among others. The transaction is expected to close around November 19, 2024. The proceeds will be used to fund research and development of the company's pipeline and general corporate purposes. The company has agreed to file a registration statement with the SEC for the resale of the shares.

Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 2024 financial results with a net loss of $7.6 million, improved from $29.3 million in Q3 2023. Revenue decreased to $4.3 million from $9.3 million year-over-year. The company maintains a strong cash position of $173.4 million, expected to fund operations into 2028.

Key developments include the first patient dosed in the ATI-2138 Phase 2a trial for atopic dermatitis, with top-line data expected in H1 2025. R&D expenses decreased to $6.0 million from $23.9 million, while G&A expenses reduced to $5.7 million from $7.1 million in the prior year period.

Aclaris Therapeutics (NASDAQ: ACRS) has announced the dosing of the first patient in its Phase 2a clinical trial of ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, for treating moderate to severe atopic dermatitis. The open-label study aims to evaluate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 over a 12-week period.

The trial plans to enroll approximately 15 subjects in the United States, with primary endpoints focusing on safety-related parameters. Secondary endpoints include EASI response measures, vIGA response, and BSA response. Aclaris expects to release topline data from this trial in the first half of 2025.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management team will engage in a fireside chat on Tuesday, September 17, 2024, at 8:00 AM ET in New York.

Investors and interested parties can access a webcast of the fireside chat through the 'Events' page in the 'Investors' section of Aclaris' website, www.aclaristx.com. The webcast will remain archived on the company's website for a minimum of 30 days, allowing for later viewing.

Aclaris Therapeutics (NASDAQ: ACRS) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Initiation of Phase 2a study activities for ATI-2138 in atopic dermatitis.
2. Strengthened balance sheet through sale of future OLUMIANT® royalties for up to $31.5 million.
3. Q2 2024 net loss of $11.0 million, compared to $29.6 million in Q2 2023.
4. Total revenue increased to $2.8 million in Q2 2024 from $1.9 million in Q2 2023.
5. R&D expenses decreased to $8.8 million from $25.3 million year-over-year.
6. Cash, cash equivalents, and marketable securities of $149.9 million as of June 30, 2024.

The company expects its current cash position, including the $26.5 million from the OLUMIANT® royalty sale, to fund operations into 2028.